Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise

This study has been completed.
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by:
McMaster University
ClinicalTrials.gov Identifier:
NCT00412204
First received: December 14, 2006
Last updated: October 20, 2009
Last verified: October 2009
  Purpose

The purpose of this study is to determine the effect of treatment with tiotropium bromide on efficiency of gas exchange and exercise performance in COPD subjects during exercise.


Condition Intervention Phase
COPD
Drug: tiotropium bromide
Other: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Tiotropium Bromide on Gas Exchange in Subjects With COPD During Exercise

Resource links provided by NLM:


Further study details as provided by McMaster University:

Primary Outcome Measures:
  • Efficiency of gas exchange Ve/VO2 and Ve/VCO2 before and after 3 weeks treatment with tiotropium compared to placebo. [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Intensity of dyspnea [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Effort during incremental and steady state exercise [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Exercise endurance capacity [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Dyspnea and leg effort [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Ventilatory capacity [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Alveolar volume [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Kco [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Cardiac output at rest and during steady state exercise before and after 3 weeks treatment with tiotropium compared to placebo. [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Ventilation/perfusion before and after 3 weeks treatment with tiotropium compared to placebo [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]
  • Ventilation during incremental and steady state exercise before and after 3 weeks treatment with tiotropium compared to placebo. [ Time Frame: Before and after 3 weeks treatment with tiotropium compared to placebo. ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: June 2006
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Tiotropium
Drug: tiotropium bromide
Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
Other Name: tiotropium bromide (Spiriva)
Placebo Comparator: 2
Placebo
Other: Placebo
Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
Other Name: placebo

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be current or ex-smokers with a cigarette smoking history of > 10 pack years.
  • All patients must have a diagnosis of COPD.
  • Patients maintained on a daily dose of inhaled corticosteroids need to be at a constant dose at 4 weeks prior to study entry.

Exclusion Criteria:

  • Patients with significant diseases other than COPD.
  • Patients with a history of a recent (i.e. six months or less) myocardial infarction.
  • Patients with unstable or life threatening cardiac arrhythmias including any patient with a newly diagnosed, clinically relevant arrhythmia on the ECG performed on Visit 1.
  • Patients who have been hospitalized for heart failure (NYHA class III or IV) within the past year.
  • Patients with a history of life threatening pulmonary obstruction, or history of cystic fibrosis or clinically evident bronchiectasis.
  • Patients who have undergone thoracotomy with pulmonary resection.
  • Patients with any respiratory infection or exacerbation in the six weeks prior to Visit 1.
  • Patients who regularly use daytime oxygen therapy for more than one hour per day and who in the investigator's opinion, will be unable to abstain from the use of oxygen therapy during testing.
  • Patients who are currently in a pulmonary rehabilitation program or who have completed a pulmonary rehabilitation program within four weeks of Visit 1.
  • Patients with known active tuberculosis.
  • Patients with a history of cancer within the past five years.
  • Pregnant or breastfeeding women or women of childbearing potential not using a medically approved means of contraception.
  • Patients with known hypersensitivity to anti-cholinergic drugs, lactose or any other components of the inhalation capsule delivery system.
  • Patients with a history of significant alcohol or drug abuse in the previous year.
  • Patients with have taken an investigational drug within 30 days or 6 half lives (whichever is greater) prior to Visit 1.
  • Patients using oral corticosteroid medication and unstable doses (i.e. less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg prednisone per day or 20 mg every other day.
  • Patients who use rescue medication (Salbutamol) more than 8 puffs/day.
  • Patients who have used tiotropium (Spiriva) within 4 weeks prior to Visit 1.
  • Patients who have frequent exacerbations which could be expected to interfere with participation in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412204

Sponsors and Collaborators
McMaster University
Boehringer Ingelheim
Investigators
Principal Investigator: Gail Gauvreau, PhD McMaster University
Study Director: Keiran Killian, MD McMaster University
  More Information

No publications provided

Responsible Party: Gail Gauvreau, McMaster University
ClinicalTrials.gov Identifier: NCT00412204     History of Changes
Other Study ID Numbers: 205.371
Study First Received: December 14, 2006
Last Updated: October 20, 2009
Health Authority: Canada: Health Canada

Keywords provided by McMaster University:
double-blind
placebo-controlled
crossover
effects of tiotropium bromide
gas exchange
Chronic Obstructive Pulmonary Disease
exercise.

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Tiotropium
Bromides
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants
Central Nervous System Agents

ClinicalTrials.gov processed this record on September 18, 2014